These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8496923)

  • 1. New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue.
    Wakselman M; Xie J; Mazaleyrat JP; Boggetto N; Vilain AC; Montagne JJ; Reboud-Ravaux M
    J Med Chem; 1993 May; 36(11):1539-47. PubMed ID: 8496923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanidinophenyl-substituted enol lactones as selective, mechanism-based inhibitors of trypsin-like serine proteases.
    Rai R; Katzenellenbogen JA
    J Med Chem; 1992 Oct; 35(22):4150-9. PubMed ID: 1433218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synthetic inhibitors targeting serine and aspartic acid proteases].
    Reboud-Ravaux MC; Boggetto ND; Doucet CE; de Rosny EH; Vergely IB; Thierry NM; Amour AJ
    J Pharm Belg; 1996; 51(3):161-4. PubMed ID: 8778349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A.
    Lewis SD; Ng AS; Baldwin JJ; Fusetani N; Naylor AM; Shafer JA
    Thromb Res; 1993 Apr; 70(2):173-90. PubMed ID: 8322286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones.
    Lijnen HR; Uytterhoeven M; Collen D
    Thromb Res; 1984 Jun; 34(5):431-7. PubMed ID: 6234678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tripeptides with non-code amino acids as potential serine proteases inhibitors.
    Markowska A; Bruzgo M; Surażyński A; Midura-Nowaczek K
    J Enzyme Inhib Med Chem; 2013 Jun; 28(3):639-43. PubMed ID: 22299583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.
    Viskupicova J; Danihelova M; Majekova M; Liptaj T; Sturdik E
    J Enzyme Inhib Med Chem; 2012 Dec; 27(6):800-9. PubMed ID: 21981000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
    Rester U; Bode W; Moser M; Parry MA; Huber R; Auerswald E
    J Mol Biol; 1999 Oct; 293(1):93-106. PubMed ID: 10512718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
    Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
    Barber CG; Dickinson RP; Fish PV
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3227-30. PubMed ID: 15149680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of plasminogen activators to suicide inactivation.
    Mor A; Reboud-Ravaux M; Mazaleyrat JP; Wakselman M
    Thromb Res Suppl; 1988; 8():35-44. PubMed ID: 3144767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
    Teno N; Otsubo T; Gohda K; Wanaka K; Sueda T; Ikeda K; Hijikata-Okunomiya A; Tsuda Y
    J Pept Sci; 2012 Oct; 18(10):620-5. PubMed ID: 22961872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1.
    de Veer SJ; Li CY; Swedberg JE; Schroeder CI; Craik DJ
    Eur J Med Chem; 2018 Jul; 155():695-704. PubMed ID: 29936356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.
    Turpeinen U; Koivunen E; Stenman UH
    Biochem J; 1988 Sep; 254(3):911-4. PubMed ID: 2461702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.